April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
The utility of PET/CT in ocular adnexal lymphoma
Author Affiliations & Notes
  • Jurij R Bilyk
    Skull Base Division, Neuro-Ophthalmology Service, Wills Eye Hospital, Philadelphia, PA
  • Ann P Murchison
    Skull Base Division, Neuro-Ophthalmology Service, Wills Eye Hospital, Philadelphia, PA
    Emergency Department, Wills Eye Hospital, Philadelphia, PA
  • Footnotes
    Commercial Relationships Jurij Bilyk, None; Ann Murchison, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4080. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jurij R Bilyk, Ann P Murchison; The utility of PET/CT in ocular adnexal lymphoma. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4080.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To study the utility of combined positron emission tomography/computed tomography (PET/CT) in the staging and management of ocular adnexal lymphoma (OAL).


A retrospective review of all patients diagnosed with OAL between January 2004 and April 2013 was performed. Patients were included if they were diagnosed with an OAL with orbital involvement confirmed by immunohistopathology and/or flow cytometry and underwent head and body PET/CT prior to the institution of therapy. Data analyzed included patient demographics, OAL diagnosis based on the World Health Organization’s reclassification of lymphoma, results of systemic staging by PET/CT, and type of therapy. Standard uptake values (SUVs) on PET/CT were also analyzed. SUVs in the ocular adnexa were analyzed separately from those in the body. Data was also analyzed after reclassifying specific lymphoma subtypes into either “indolent” or “aggressive” categories, based on known clinical behavior of each lymphoma subtype. Descriptive statistics and analysis (Fisher exact test and Wilcox sum rank test) for correlations were carried out with SPSS 16.0.1.


Forty-one patients met the inclusion criteria. Analysis of SUVs showed a statistically significant difference in orbital SUVs between indolent and aggressive lymphoma subtypes (p=0.003). However, no significant difference was noted when comparing body SUVs (p=0.2225). Comparison of the distribution of lymphoma subtypes across initial stages with PET alone was compared to published reports on staging distributions utilizing additional modalities (CT, MRI, bone marrow biopsy), and no statistically significant difference was found. Of note, although 12 of 27 (44%) indolent OAL were stage I compared to only 2 of 14 (14%) aggressive OAL, this difference was not statistically significant (p=0.1928).


The orbital SUV of indolent OAL is significantly lower than of aggressive OAL, but no difference was noted in body SUVs. PET appears to upstage indolent OAL when compared to previous studies, but this finding must be tempered by known limitations of PET in orbital disease and in non-Hodgkin lymphoma (NHL), including resolution, background metabolic activity of the brain, and variable tracer uptake in indolent NHL. Based on this limited initial study, the utility of PET/CT in the staging of indolent lymphoma subtypes remains unproven.

Keywords: 631 orbit  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.